Humanigen, Inc.

HGENQ

US4448632038

Pharmaceuticals

Delayed OTC Markets Other stock markets 09:30:59 2024-05-17 am EDT			5-day change	1st Jan Change
0.0001 ^USD	-50.00%		-50.00%	-91.67%

Apr. 12	Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	CI
Mar. 08	Final DIP Financing Approved for Humanigen, Inc.	CI

Humanigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 05, 2022 at 04:16 pm EDT

Humanigen, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 1.04 million compared to USD 0.486 million a year ago. Net loss was USD 21.28 million compared to USD 65.57 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 1.25 a year ago.

Latest news about Humanigen, Inc.

Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	Apr. 12	CI
Final DIP Financing Approved for Humanigen, Inc.	Mar. 07	CI
Motion for Asset Sale Approved for Humanigen, Inc.	Feb. 16	CI
Notice for Auction Cancellation Filed by Humanigen, Inc.	Feb. 12	CI
Bidding Procedure Approved for Humanigen, Inc.	Jan. 24	CI
News Highlights : Top Company News of the Day	Jan. 04	DJ
19 treatment developer Humanigen files for Chapter 11 bankruptcy	Jan. 04	RE
Motion for Asset Sale Filed by Humanigen, Inc.	Jan. 03	CI
Humanigen, Inc. Filed for Bankruptcy	Jan. 03	CI
Interim DIP Financing Approved for Humanigen, Inc.	Jan. 02	CI
Xspray Pharma Names Chief Commercial Officer	23-09-15	MT
Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer	23-09-14	CI
North American Morning Briefing : PCE Inflation -2-	23-08-31	DJ
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index	23-07-28	CI
Sector Update: Health Care Stocks Steady in Late Afternoon Trading	23-07-25	MT
Sector Update: Health Care Stocks Steady Tuesday Afternoon	23-07-25	MT
Sector Update: Health Care	23-07-25	MT
Humanigen Issues 'Going Concern' Warning; Shares Hit 52-Week Low	23-07-25	MT
Humanigen, Inc. Announces Board Changes	23-07-25	CI
Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index	23-07-25	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Value Index	23-06-23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell 3000E Value Index	23-06-23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Growth Index	23-06-23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Index	23-06-23	CI

Chart Humanigen, Inc.

Duration

Period

More charts

Company Profile

Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.

Sector

Pharmaceuticals

More about the company

	1st Jan change	Capi.
HUMANIGEN, INC.	-91.67%	23.82K
CSL LIMITED	-2.32%	92.59B
SAMSUNG BIOLOGICS CO.,LTD.	+3.16%	41.43B
BIOGEN INC.	-12.47%	33.49B
BIOMARIN PHARMACEUTICAL INC.	-20.78%	14.62B
INCYTE CORPORATION	-9.71%	12.77B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.25%	11.58B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.00%	11.35B
SWEDISH ORPHAN BIOVITRUM AB	+4.42%	8.97B
INNOVENT BIOLOGICS, INC.	-6.32%	8.3B

Biopharmaceuticals

Humanigen, Inc.

Equities

HGENQ

US4448632038

Pharmaceuticals

Humanigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

Latest news about Humanigen, Inc.

Chart Humanigen, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals